683 Capital Management LLC Has $1.60 Million Stake in PLx Pharma Inc (PLXP)

683 Capital Management LLC decreased its holdings in shares of PLx Pharma Inc (NASDAQ:PLXP) by 14.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 249,300 shares of the biotechnology company’s stock after selling 41,609 shares during the quarter. 683 Capital Management LLC owned 2.86% of PLx Pharma worth $1,603,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. University of Texas Investment Managment Co. purchased a new stake in PLx Pharma in the second quarter worth approximately $385,000. Susquehanna International Group LLP purchased a new stake in PLx Pharma in the second quarter worth approximately $1,413,000. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new stake in PLx Pharma in the third quarter worth approximately $145,000. 21.87% of the stock is owned by institutional investors.

Several brokerages have issued reports on PLXP. Zacks Investment Research lowered PLx Pharma from a “buy” rating to a “sell” rating in a research note on Tuesday, October 3rd. ValuEngine raised PLx Pharma from a “strong sell” rating to a “sell” rating in a research note on Monday, December 4th.

PLx Pharma Inc (NASDAQ PLXP) traded up $0.25 during trading hours on Friday, hitting $6.90. The stock had a trading volume of 10,172 shares, compared to its average volume of 8,034. PLx Pharma Inc has a 52-week low of $5.60 and a 52-week high of $14.00. The company has a quick ratio of 8.88, a current ratio of 8.99 and a debt-to-equity ratio of 0.56.

WARNING: This piece of content was originally published by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://weekherald.com/2017/12/30/683-capital-management-llc-sells-41609-shares-of-plx-pharma-inc-plxp.html.

PLx Pharma Company Profile

PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply